RiaSTAP

CSL Behring GmbH🇺🇸 United States

FDA Page

Effective Date: Dec 29, 2025
Approval ID: 903dc8d0-39da-462c-9dac-004e0c7a26cc
Products: 2 registered
Version: 19

Regulatory Information

Labeling Type

PLASMA DERIVATIVE

Status

Approved

Full Title

These highlights do not include all the information needed to use RIASTAP safely and effectively. See full prescribing information for RIASTAP. RIASTAP, Fibrinogen Concentrate (Human)Lyophilized Powder for Solution for Intravenous InjectionInitial U.S. Approval: 2009

Quick Stats

Total Products2

Labelers1

Label Sections35

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.